Innova Captab Peer Comparison

NSE: INNOVACAP | BSE: 544067

₹1,023.80

₹-29.60 (-2.81%)

As on 15-Oct-2026IST

Market cap

₹5,871 Cr

Revenue (TTM)

₹1,749 Cr

P/E Ratio

37.6

P/B Ratio

5.2

Div. Yield

0.2 %

Edit

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	5,871	31,680	25,868	25,655	24,429
Revenue (₹ Cr)	1,749	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	156.29	414.00	-371.81	387.35	288.22
Net Margin (%)	8.89	11.23	-3.93	26.01	14.79
RoE (%)	14.87	8.38	-3.85	25.18	29.77
Price to Earnings	37.56	77.46	--	66.42	84.76
Price-To-Book	5.17	6.29	3.23	14.87	18.20

Income Statement (₹ Cr)

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	1,749.33	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	1,758.75	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	1,489.86	2,792.00	8,195.15	919.25	1,485.56
EBITDA	259.47	772.00	1,010.13	542.56	450.24
Depreciation	45.85	226.00	857.51	37.68	50.83
EBIT	213.62	546.00	152.62	504.88	399.41
Interest	18.47	217.00	342.73	3.77	40.84
Other Income	9.42	122.00	244.31	27.45	12.78
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	204.57	463.00	-162.68	528.56	371.35
Provision for Tax	48.28	49.00	209.13	141.21	83.14
Profit after Tax	156.29	414.00	-371.81	387.35	288.22

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	1,081.51	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	261.72	1,712.00	5,044.14	42.40	202.03
Current Liabilities	494.58	1,622.00	4,758.28	230.82	835.87
Total Liabilities	1,858.06	8,578.00	17,723.32	1,983.96	2,326.71

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	815.59	5,343.00	10,211.52	1,026.85	519.60
Current Assets	922.96	2,606.00	7,191.66	881.27	1,681.81
Total Assets	1,858.06	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	342.67	2,125.00	5,495.48	26.49	259.37
Net Current Assets	428.38	984.00	2,433.38	650.46	845.94
Contingent Liabilities	--	768.26	95.72	17.25	19.09

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	116.52	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	-107.12	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	-21.72	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	-12.32	95.00	787.59	30.33	78.39

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	15.04	6.79	1.24	32.42	29.22
ROE (%)	14.87	8.38	-3.85	25.18	29.77
ROA (%)	9.14	4.94	-2.21	21.93	24.77
EBIT Margin (%)	12.21	15.32	1.66	34.54	20.63
Net Margin (%)	8.89	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	34.47	18.37	0.78	40.90	46.65
EBIT Growth (%)	29.38	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	21.36	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	21.36	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	13.69	13.47	0.33	26.03	144.31

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	37.44	79.50	-82.58	66.42	83.45
Price / Book Value	5.16	6.29	3.23	14.87	18.20
Dividend Yield (%)	0.20	0.00	0.00	0.08	0.10
EV/EBITDA	23.70	42.93	29.68	46.92	54.06
Market Cap (₹ Cr)	3,933.72	19,071.62	18,108.89	20,944.75	12,753.19

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.20	0.31	0.53	0.02	0.11
Short term debt to equity ratio	0.09	0.09	0.09	0.02	0.05
Current Ratio	1.87	1.61	1.51	3.82	2.01
Quick Ratio	1.29	1.06	0.87	2.82	1.14
Interest Coverage	12.08	3.13	0.53	141.16	10.09

	Innova Captab	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	25.00	16.50	23.44	24.80	26.28
Asset Turnover	1.02	0.43	0.55	0.83	1.66
Receivable days	84.59	58.75	78.20	88.98	40.13
Inventory Days	54.04	75.82	93.30	56.04	60.29
Payable days	114.83	186.21	226.14	99.95	232.47
Cash Conversion Cycle	23.80	-51.64	-54.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.